We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
deCODE Receives California Clinical Laboratory License
News

deCODE Receives California Clinical Laboratory License

deCODE Receives California Clinical Laboratory License
News

deCODE Receives California Clinical Laboratory License

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "deCODE Receives California Clinical Laboratory License"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

deCODE genetics has announced that it has received a clinical laboratory license from the State of California. The quality and scale of deCODE’s in-house, CLIA-registered genotyping laboratory underpins deCODE’s global leadership in the discovery of variations in the sequence of the human genome conferring risk of common diseases.

The same staff and facility also process deCODE’s DNA-based reference laboratory tests for gauging individual risk of major public health challenges ranging from heart attack to breast cancer, as well as the company’s deCODEme™ scans. The company says that with this license, California residents can now benefit from the unrivalled quality of deCODE products for understanding risk and, working with their physicians, empowering the prevention of common diseases.

Through its reference laboratory testing service, www.decodediagnostics.com, deCODE offers DNA-based tests for assessing individual risk of heart attack, type 2 diabetes, stroke, breast cancer, prostate cancer, and glaucoma.

deCODEme™ is said to be the world’s first retail genome analysis service, available at www.decodeme.com. The full genome Complete Scan scan and the Cardio and Cancer scans build on deCODE’s discovery of common variations in the sequence of the human genome conferring increased risk of common diseases.
Advertisement